EN DE
Watch Kane Biotech Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kane Biotech Inc (KNE) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Kane Biotech Inc stock C$0.03, price C$0.03, that is 8.4% below the price, quality 16 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA4838092084

KB Kane Biotech Inc logo Thin data Nov 13, 2026

Kane Biotech Inc

KNE · V

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Fair value C$0.0275 · Fairly valued 
Negative equity (buybacks among others) 
Revenue last quarter 71% below a year ago. 
Quality 16/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −20.4 %/yr in CAD) 
Negative free cash flow 
Trails peers (1/4) 
Narrow moat 12/100
Thin data 
Estimate⚠ Thinly traded
Watch Kane Biotech Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$0.1900 C$0.0200 Fair Value C$0.0275 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range C$0.0200 – C$0.1900 · fair‑value band C$0.0259 – C$0.0291 · the C$0.0300 price screens above the C$0.0275 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Kane Biotech in your weekly email

Every Wednesday you see whether Kane Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.

Show moreShow less

The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections.

Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name.

In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand.

Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate acne vulgaris.

Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Stock analysis

Kane Biotech Inc (KNE) currently trades at C$0.0300, while our estimate is C$0.0275, so the stock looks roughly fairly valued today (gap 9.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$0.0259 (bear) to C$0.0291 (bull), the price of C$0.0300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Kane Biotech Inc reported revenue of C$428K in FY2025 versus C$1.6M in FY2021, a compound −28.2%/yr. Reported net income was −C$2.7M in FY2025.

Key figures

Market cap C$6.2M (≈ $4.3M) Micro · EPS (TTM) C$−0.0200 · Return on equity −597% · Return on assets (EBIT) −92.2% (5-year average) · Operating margin −9,634% · Revenue growth (YoY) −70.9% · Free cash flow −C$3.4M · Net debt C$962K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 40% below its 52-week high and 50% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −8%, KNE screens richer than that median.

Fair Value

Bear C$0.0259 Fair Value C$0.0275 Bull C$0.0291
Price C$0.0300 · Downside -8.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 16/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 33
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−79.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−45.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.4%
Start year 2020 (pandemic). Over 10 years: +15.1% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−314.9% (2020) → −620.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch KNE, get fair value alerts →

Compare Kane Biotech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 16 · Bottom 25%
Fair Value upside −8.3% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −99.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −70.9% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs KNE
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs KNE
Samsung Biologics Co 207940 1,411,000 KRW 1,573,000 KRW +11% vs KNE
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs KNE
argenx SE ARGX $960.04 $908.40 −5% vs KNE
CSL Limited CSL A$202.92 A$183.54 −10% vs KNE
Moderna, Inc MRNA $223.37 $139.99 −37% vs KNE
BeOne Medicines AG 6160 HK$249.80 HK$152.80 −39% vs KNE
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs KNE
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs KNE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kane Biotech Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kane Biotech Inc Fair Value". https://www.fairvalue-calculator.com/stock/KNE

Frequently asked questions

Is Kane Biotech Inc (KNE) overvalued or undervalued?
As of Nov 13, 2026, our estimate of fair value is C$0.0275 versus a price of C$0.0300, about 8% lower (fairly valued).
What is the fair value of KNE?
Our estimate for Kane Biotech Inc is C$0.0275 (as of Nov 13, 2026), built from audited fundamentals. The current price: C$0.0300.
What is the quality score of KNE?
Kane Biotech Inc has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kane Biotech Inc (KNE)?
Our calculated price target is the estimate of C$0.0275 (as of Nov 13, 2026). Cautious scenario C$0.0259, optimistic scenario C$0.0291. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Kane Biotech Inc stock forecast for 2026?
Our estimate puts fair value at C$0.0275, about 8% lower versus a price of C$0.0300 (fairly valued). Cautious scenario C$0.0259, optimistic scenario C$0.0291. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Kane Biotech Inc (KNE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kane Biotech Inc it is C$0.0275 per share (as of Nov 13, 2026), against a price of C$0.0300.
Is Kane Biotech Inc stock overvalued or undervalued in 2026?
As of Nov 13, 2026, KNE trades above its calculated fair value: price C$0.0300, fair value C$0.0275, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KNE?
No. The price is what the market pays today (C$0.0300); the fair value is what the company's own numbers justify (C$0.0275). For Kane Biotech Inc the two are C$0.0025 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kane Biotech Inc worth?
The market values Kane Biotech Inc at about C$6.2M (market capitalisation, as of Nov 13, 2026). Per share that is C$0.0300; our models calculate a fair value of C$0.0275 per share.
What do the bullish and bearish scenarios say about KNE?
Our models span a range for Kane Biotech Inc: cautious scenario C$0.0259, base C$0.0275, optimistic C$0.0291 per share (as of Nov 13, 2026, price C$0.0300). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kane Biotech Inc (KNE)?
Balance-sheet figures for Kane Biotech Inc (as of Nov 13, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
How far is KNE from its 52-week high?
Kane Biotech Inc trades at C$0.0300, about 40% below its 52-week high of C$0.0500 and 50% above the low of C$0.0200 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.0275 is for.
Which stocks are comparable to Kane Biotech Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kane Biotech Inc stock attractive at the current price?
The data as of Nov 13, 2026: price C$0.0300, calculated fair value C$0.0275 (−8%), Quality Score 16/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Kane Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kane Biotech Inc (KNE)?
The closing price on Nov 13, 2026 was C$0.0300. Our estimate is C$0.0275, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kane Biotech Inc right now?
The price sits above even our optimistic bull case (C$0.0291). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (C$0.0259 to C$0.0291), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Kane Biotech Inc

How large is the market capitalisation of Kane Biotech Inc (KNE)?
The market capitalisation of Kane Biotech Inc is C$6.2M (≈ $4.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Kane Biotech Inc (KNE)?
Earnings per share at Kane Biotech Inc are C$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Kane Biotech Inc (KNE)?
The return on equity (ROE) of Kane Biotech Inc is −597% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kane Biotech Inc (KNE)?
On an EBIT basis the return on assets of Kane Biotech Inc is −92.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kane Biotech Inc (KNE)?
The operating margin of Kane Biotech Inc is −9,634% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kane Biotech Inc (KNE)?
Revenue at Kane Biotech Inc is growing −70.9% versus a year earlier (3y avg −45.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Kane Biotech Inc (KNE) generate?
The free cash flow of Kane Biotech Inc is −C$3.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kane Biotech Inc (KNE) carry?
The net debt of Kane Biotech Inc is C$962K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Kane Biotech Inc in the live analysis

One click puts Kane Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.